Highlights of weekly biotech stock moves
Regulatory, clinical and other milestones
Acorda Therapeutics Inc. (NASDAQ:ACOR) fell $3.51 (10%) to $32.39 on Friday after FDA asked for an additional clinical trial in a complete response letter for Plumiaz diazepam nasal spray to treat acute repetitive seizures in epileptics.
Acorda was off $1.07 on the week.
Biota Pharmaceuticals Inc. (NASDAQ:BOTA) fell $1.89 (34%) to $3.68 on Tuesday after reporting that HHS's Office of the Assistant Secretary for Preparedness and Response (ASPR) and Biomedical Advanced Research and Development Authority (BARDA) issued a stop-work order for laninamivir octanoate. Biota is developing the influenza product under a BARDA contract worth up to $231 million.
The order is in effect pending a decision from HHS, which the company said it expects "within the next week or so."
Biota lost $1.84 (34%) to $3.59 on the week.
The Medicines Co. (NASDAQ:MDCO) was up $0.41 to $26.46 last week. FDA issued a complete response letter for cangrelor for its two proposed indications: to reduce thrombotic events in patients with coronary artery disease (CAD) undergoing percutaneous coronary intervention (PCI); and as bridging therapy for patients with stents who are at increased risk for thrombotic events when oral P2Y12